Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph

December 28, 2021 updated by: Visionary Intelligence Ltd.

A Prospective, Multicenter, Blinded Reading, Self Controlled, Superiority Priority Clinical Trial of Assisted Fundus Image Diagnosis Software for the Diagnosis of Multiple Eye Fundus Diseases

Blindness can be caused by many ocular diseases, such as diabetic retinopathy, retinal vein occlusion, age-related macular degeneration, pathologic myopia and glaucoma. Without timely diagnosis and adequate medical intervention, the visual impairment can become a great burden on individuals as well as the society. It is estimated that China has 110 million patients under the attack of diabetes, 180 million patients with hypertension, 120 million patients suffering from high myopia and 200 million people over 60 years old, which suggest a huge population at the risk of blindness. Despite of this crisis in public health, our society has no more than 3,000 ophthalmologists majoring in fundus oculi disease currently. As most of them assembling in metropolitan cities, health system in this field is frail in primary hospitals. Owing to this unreasonable distribution of medical resources, providing medical service to hundreds of millions of potential patients threatened with blindness is almost impossible.

To solve this problem, this software (MCS) was developed as a computer-aided diagnosis to help junior ophthalmologists to detect 13 major retina diseases from color fundus photographs. This study has been designed to validate the safety and efficiency of this device.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

As a prospective clinical trial, This study enjoys multicentric, blind film reading, self-control and superiority test design. In total, 1,500 retinal fundus images from 750 individuals in need of fundus examination (one image for every single eye) were selected. Then a test group, along with a control group was set up in our study. For the test group, ophthalmologists read images with the aid of the assistant software(MCS). In contrast, the same work in the control group was finished by ophthalmologists independently. Meanwhile, the gold standard were obtained from the cooperation of senior ophthalmologists. Diagnoses of both groups were compared with those of the gold standard, thus the investigators could evaluated the safety and effectiveness of this assistant software in diagnosis.

The primary endpoint of this study is the superiority of the consistency rate of the test group. A diagnosis for an image is consistent if it gives the same negative result as the reference standard, or reveals any one condition indicated by the reference standard. The consistency rate is the rate of consistent diagnoses for all the involved images. One control group is designed, where each doctor reads and diagnoses, and give at most 3 possible conditions for each image. In the test group, doctors do the same thing with the help of this software. The investigators in the test group and control group are the same and they are chosen from ophthalmologists with 1~3 years experience. The reference standard of each fundus image is collaboratively given by retinal specialists/fellows from 5 centers. The investigator of XieHe center is the arbitrator if full consensus cannot be reached for any image during the building of reference standard.

Study Type

Observational

Enrollment (Actual)

748

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Beijing
      • BeiJing, Beijing, China, 100730
        • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    • Hebei
      • Shijia Zhuang, Hebei, China
        • The Second Hospital of Hebei Medical University
    • Sichuan
      • Chengdu, Sichuan, China
        • West China Hospital of Sichuan University
    • Tianjin
      • Tianjin, Tianjin, China
        • Tianjin Medical University Eye Hospital
    • Zhejiang
      • Wenzhou, Zhejiang, China
        • Eye Hospital, WMU Zhejiang Eye Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Any patients who meet the eligibility criteria.

Description

Inclusion Criteria:

  • Age between 18 and 75.
  • Anyone need to take fundus photograph in clinical.
  • Understand the study and volunteer to sign the informed consent.
  • For fundus images of participants, the optic disc, fovea, the upper and lower vessel bow should be included in the fundus field.

Exclusion Criteria:

  • Participants has any eye that cannot take fundus photos.
  • Participants have joined or is participating in other clinical trial within one month.
  • Participants who have any other issue that cannot be enrolled.
  • Participants with cloudy refractive media that cannot take fundus photos or get clouding fundus photos.
  • Participants with low quality fundus photos like incompetent vision field, overexposed/underexposed, out of focus, too many shadow or dirties and so on.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Test Group
ophthalmologists read images applying the assistant software
Diagnostic test: Software assisted imaging diagnosis
In the test group, diagnoses are given with the help of the software.
Control Group
ophthalmologists read images independently

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
consistent rate of diagnoses
Time Frame: through study completion, an average of 1 year

Formula for calculation: consistent rate of diagnoses=number of images with consistent diagnosis/ total number of images × 100%.

Method: the diagnoses from the test group and the control group were compared with diagnoses from the gold standard. For each image, if one or more diagnoses were consistent with those of the gold standard, which means at least one label existed in the intersection of diagnoses from the test group(or the control group)and those from the gold standard, it would be classified as "image with consistent diagnosis". Otherwise, it would be classified as "image without consistent diagnosis". After above-mentioned steps, the investigators had obtained the number of images with consistent diagnosis in each group. As images with 1-2 labels account for the majority in actual work, the investigators stipulated that each image in both groups could be marked with 3 labels at most in case of invalid improvement in consistent rate owing to multiple selections.
through study completion, an average of 1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
sensitivity and specificity of software's diagnoses for each diseases
Time Frame: through study completion, an average of 1 year
sensitivity and specificity of software's diagnoses for each diseases
through study completion, an average of 1 year
PPV and NPV of software's diagnoses for each diseases
Time Frame: through study completion, an average of 1 year
PPV(Positive Predictive Value) and NPV(Negative Predictive Value) of software's diagnoses for each diseases
through study completion, an average of 1 year
full coincidence rate of software's diagnoses
Time Frame: through study completion, an average of 1 year
The full consistency rate is the rate of fully consistent diagnoses in the set. A diagnosis is fully consistent it is exactly the same as the reference standard.
through study completion, an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Visionary Intelligence Ltd.

Collaborators

Peking University First Hospital
Beijing Municipal Science & Technology Commission

Investigators

  • Study Chair: You xin Chen, PHD, Peking Union Medical College

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 10, 2020

Primary Completion (Actual)

March 10, 2021

Study Completion (Actual)

May 30, 2021

Study Registration Dates

First Submitted

January 17, 2021

First Submitted That Met QC Criteria

January 20, 2021

First Posted (Actual)

January 25, 2021

Study Record Updates

Last Update Posted (Actual)

December 30, 2021

Last Update Submitted That Met QC Criteria

December 28, 2021

Last Verified

December 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BLG-20200101

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetic Retinopathy

Clinical Trials on Software assisted imaging diagnosis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe